echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > What happened to the pharmaceutical companies after the special centralized procurement of insulin was implemented?

    What happened to the pharmaceutical companies after the special centralized procurement of insulin was implemented?

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Market Analysis] After the selected varieties of insulin special centralized procurement with an average price drop of 48% are implemented, it is a boon for the majority of patients, and it is a huge test for the selected manufacturer.
    Judging from the semi-annual reports of Chinese selected pharmaceutical companies, the price reduction brought about by the special centralized procurement of insulin has initially affected the performance of many companies: Tonghua Dongbao expects that in the first half of 2022, the non-net profit will drop by 96% year-on-yea.
    It reflects the real situation of the main business of the compan.
    As for the reason for the decline, the company said that the main reason for the decline is that the price of insulin products has fallen; Gan and Lee Pharmaceutical won the bid for six products in the centralized insulin procurement, but it is expected to lose 168 million yuan in the first half of this year- 200 million yuan, a year-on-year change from profit to loss, the company said that while it obtained a higher contracted purchase volume, the product price dropped significantl.
    Due to the short execution time of centralized procurement, the increase in sales volume in the short term cannot yet offset the impact of price declin.
    In order to hedge the impact of centralized procurement, pharmaceutical companies need to accelerate the transformation of varietie.
    At present, selected companies including Tonghua Dongbao and Ganli Pharmaceutical are increasing R&D innovation and enriching R&D pipeline.
    Among them, Gan & Lee Pharmaceutical's R&D expenses increased significantly year-on-year in the first half of this yea.
    Since the beginning of this year, the research and development of new drugs has been progressing continuousl.
    The company focuses on the research and development of diabetes, and has successfully expanded into anti-tumor, autoimmune diseases, blood diseases and other biological and chemical drug innovation field.
    Examples include: the company's drug candidate GLR2007 was granted orphan drug designation by the European Medicines Agency for the treatment of glioma, and obtained the FDA fast track review qualification for the treatment of glioblastoma; independent research and development The GZR18 of GZR18 is undergoing Phase II clinical trials in China, and the first subject has been successfully administered recentl.
    The drug is a weekly preparation of glucagon-like peptide-1 (GLP-1) receptor agonist, and is undergoing phase Ib/IIa clinical trials for type 2 diabetes, obesity and overweight weight managemen.
    The market has broad prospects; in addition, GZR4, a class 1 innovative therapeutic biological product independently developed by the company, has also recently obtained the "Drug Clinical Trial Approval Notice", and no weekly insulin preparation products have been approved for marketing in the worl.
    Tonghua Dongbao is also accelerating its layout through R&D innovatio.
    On July 15, the company announced that the clinical trial application for insulin degludec has been accepted by the CD.
    Insulin degludec is an ultra-long-acting basal insulin analog with a long half-life, With the characteristics of stable and long-lasting effect and lower risk of hypoglycemia, there is currently no biosimilar drug on the market globall.
    Recently, Tonghua Dongbao also stated on the interactive platform that it will focus on the third-generation insulin market in the field of insulin research and developmen.
    In addition, the company is also developing GLP-1 receptor agonists, including liraglutide injection and semaglutide injectio.
    Liquid and high clinical value of chemical drugs oral hypoglycemic drugs, including repaglina tablets, empagliflozin raw materials and tablets,et.
    In the short term, centralized insulin procurement will affect the profits of pharmaceutical companies, but in the long run, it is still expected to bring growth to the compan.
    Previously, relevant persons of Gan & Lee Pharmaceuticals once said that in the centralized procurement in 2021, the company's 6 products won the bid across the board, bringing a considerable amount of new agreements and ensuring the company's product sales channels and sales; in the long run, the centralized procurement will Promote the company's market shar.
    China is a big country with diabetes, and the market demand of the majority of patients for diabetes treatment drugs is continuously expandin.
    According to the International Diabetes Federation (IDF) data, by 2030, the size of China's diabetes drug market is expected to exceed 100 billion yua.
    The industry believes that through centralized procurement, it is expected to accelerate the substitution of third-generation insulin analogs for second-generation insulin, and at the same time, it is also expected to break the situation that imported products occupy most of the market for a long tim.

    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.